Propanc Biopharma annual return on equity
2011
2012
2025
Propanc Biopharma Return on Equity (ROE) Growth & History (PPCB)
Propanc Biopharma's return on equity was −1,163.67% for fiscal 2025.
View full Propanc Biopharma company overviewPropanc Biopharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-06-30 | −1,163.67% | — |
| 2012 | 2012-06-30 | −229.39% | −187.69 pp |
| 2011 | 2011-06-30 | −41.70% | — |
Propanc Biopharma quarterly return on equity
Q2.12
Q3.12
Q4.12
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-03-31 | −62.72% | +713.35 pp |
| Q2 2026 | 2025-12-31 | −24.92% | — |
| Q1 2026 | 2025-09-30 | −34.23% | — |
| Q4 2025 | 2025-06-30 | −25.45% | — |
| Q3 2025 | 2025-03-31 | −776.08% | — |
| Q4 2012 | 2012-06-30 | −448.22% | — |
| Q3 2012 | 2012-03-31 | −99.96% | — |
| Q2 2012 | 2011-12-31 | −36.10% | — |
Propanc Biopharma return on equity trends
Between the periods ended 2011-06-30 and 2025-06-30, Propanc Biopharma's return on equity decreased from −41.70% to −1,163.67%, a change of −1121.97 percentage points. The latest reported quarter, Q3 2026, shows −62.72%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Propanc Biopharma source filings ↗